GlassScriptPhysician profile
Ericka P Greene
NPI 1720018021
$72,334.53
in general payments reported to CMS, 2019-2025
40 companies · $6,121 in 2025
The $6,121 reported for 2025 was more than what 86% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $29K · 2020: $12K · 2021: $7,458 · 2022: $14K · 2023: $3,100 · 2024: $584 · 2025: $6,121.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $5,433 · Food and Beverage: $2,918 · Travel and Lodging: $1,455.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $5,432.50 |
| Food and Beverage | $2,918.05 |
| Travel and Lodging | $1,454.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $49,896.90 | 2019-2025 | Soliris, Ultomiris |
| Ucb, INC. | $6,291.99 | 2021-2025 | Rystiggo |
| Novartis Pharmaceuticals Corporation | $5,421.35 | 2021-2025 | |
| Csl Behring | $4,636.99 | 2019-2025 | Hizentra |
| Catalyst Pharmaceuticals, INC. | $2,108.10 | 2019-2025 | |
| Argenx US, INC. | $554.75 | 2022-2025 | Vyvgart, Vyvgart Hytrulo |
| Allergan, INC. | $550.94 | 2019-2022 | |
| Pfizer INC. | $290.49 | 2023-2025 | |
| Avanir Pharmaceuticals, INC. | $281.89 | 2019-2022 | |
| Emd Serono, INC. | $260.79 | 2019-2023 | Mavenclad |
| Abbvie INC. | $245.59 | 2021-2025 | Botox |
| Sunovion Pharmaceuticals INC. | $183.64 | 2019-2020 | |
| Hospira, INC. | $176.15 | 2024-2025 | |
| Tanabe Pharma America, INC. | $159.05 | 2021-2025 | Radicava |
| Biogen, INC. | $135.91 | 2021-2025 | Skyclarys, Spinraza, Vumerity |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ericka Greene listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.